Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients

Journal of Clinical Microbiology

Volumn 42, Issue 12, 2004, Pages 5846-5848

  Burn, A K ^a   Fothergill, A W ^a,b   Kirkpatrick, W R ^a   Coco, B J ^a   Patterson, T F ^a,b   McCarthy, D I ^a,b   Rinaldi, M G ^a,b   Redding, S W ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS ISOLATION; GROWTH INHIBITION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS, ORAL; FLUCONAZOLE; HEAD AND NECK NEOPLASMS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA GLABRATA; FUNGI;

EID: 10844265209     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.12.5846-5848.2004     Document Type: Article

References (16)

1. Di Francesco, L., F. Barchiesi, F. Caselli, O. Cirioni, and F. Scalise. 1999. Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. J. Med. Microbiol. 48:955-963.
2. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
3. Marr, K. A., C. N. Lyons, T. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
4. Muysers, R. B. R., K. L. Goa, and L. J. Scott. 2002. Voriconazole: in the treatment of invasive aspergillosis. Drugs 62:2655-2664.
5. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6. Pappas, P. G., J. H. Rex, J. D. Sobel, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
7. Patterson, T. F., S. G. Revankar, W. R. Kirkpatrick, et al. 1996. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J. Clin. Microbiol. 34:1794-1797.
8. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39:3254-3259.
9. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
10. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
11. Ramirez-Amador, V., S. Silverman, Jr., P. Mayer, M. Tyler, and J. Quivey. 1997. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 84:149-153.
12. Redding, S. W., W. R. Kirkpatrick, B. J. Coco, L. Sadkowski, A. W. Fothergill, M. G. Rinaldi, T. Y. Eng, and T. F. Patterson. 2002. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J. Clin. Microbiol. 40:1879-1881.
13. Redding, S. W., R. C. Zellars, W. R. Kirkpatrick, R. K. McAtee, M. A. Caceres, A. W. Fothergill, J. L. Lopez-Ribot, C. W. Bailey, M. G. Rinaldi, and T. F. Patterson. 1999. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J. Clin. Microbiol. 37:3896-3900.
14. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
15. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
16. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.